THRA and bone neoplasm: High-level amplification of TGFβ2 (1q41), CCND3 (6p21), WI-6509 (11qtel), SHGC-5557 (12ptel), TCL1A (14q32.1), CREBBP (16q13.3), HIC1 (17p13.3), THRA (17q11.2), AFM217YD10 (17qtel), LAMA3 (18q11.2), RUNX1 (21q22.3) and D22S543 (22q11), was commonly observed in aggressive bone tumors.